论文部分内容阅读
目的：探讨αＬ岩藻糖苷酶ＡＦＵ对原发性肝癌诊断价值。方法：应用分光比色法测定３６例原发性肝癌（ＰＨＣ）、５例肝硬变、４例肝良性占位病变、４０例消化系统恶性肿瘤和４０例正常健康人血清αＬ岩藻糖苷酶（ＡＦＵ）活性值。结果：ＰＨＣ组血清ＡＦＵ活性显著高于其余各组（Ｐ＜００１）；ＡＦＵ对ＰＨＣ诊断敏感度、特异性、准确度分别为８０６％、８９９％、８７２％，阳性预报率、阴性预报率分别为７６２％、９２０％；ＡＦＵ与ＡＦＰ联合检测可使ＰＨＣ诊断阳性率提高到９１７％。结论：ＡＦＵ可作为原发性肝癌的血清标志物，对ＡＦＰ阴性病例尤有价值。
Objective: To investigate the diagnostic value of αLfucosidase AFU in primary liver cancer. Methods: Spectrophotometric method was used to determine 36 cases of primary liver cancer (PHC), 5 cases of cirrhosis, 4 cases of benign liver lesions, 40 cases of digestive system malignancies, and 40 cases of normal healthy human serum α-L Algalase (AFU) activity value. Results: The serum AFU activity in PHC group was significantly higher than that in other groups (P<001). The sensitivity, specificity, and accuracy of AFU in diagnosis of PHC were 80.6%, 89.9%, and 87.4%, respectively. Positive predictive rate and negative predictive rate were 76. 2% and 92.0%, respectively; combined detection of AFU and AFP increased the positive rate of PHC diagnosis to 91.7%. Conclusion: AFU can be used as a serum marker for primary hepatocellular carcinoma, and it is especially valuable for AFP-negative cases.